We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Applied Genetic Technologies Corporation | NASDAQ:AGTC | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.3936 | 0.4329 | 0.3739 | 0 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Applied Genetic Technologies Corp. (AGTC) shares fell 48% to $3.40 Thursday.
The clinical-stage biotechnology company Wednesday said results from an X-linked retinoschisis, or XLRS, study support general safety and tolerability of its gene delivery platform, but didn't demonstrate signs of clinical activity at the interim six-month time point.
The company said Biogen (BIIB) is terminating a collaboration agreement. Applied Genetic said it will regain full rights to the XLRS and X-linked retinitis pigmentosa, or XLRP, programs and the three other partnered discovery programs following Biogen's termination, effective on March 8.
Applied Genetic said it will complete patient monitoring activities on the XLRS program, but won't further develop the product. It said it plans to advance the XLRP program, and will determine next steps for the three discovery programs over the next several months.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 13, 2018 12:09 ET (17:09 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Applied Genetic Technolo... Chart |
1 Month Applied Genetic Technolo... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
